s
seragy
Germany · Biotech
Quantitative biomarkers for diseases driven by protein aggregation.
Product
seragy develops biomarkers that help drug developers characterize abnormal protein aggregation. Its SeRAS platform aims to measure molecular patterns and disease subtypes across conditions including Parkinson’s, Alzheimer’s and ALS.
The Hanover group was founded as Prosperodes GmbH. seragy holding owns intellectual property and licenses the technology; seragy analytics carries out operational services and partner projects. Its platform combines biochemical assays, sensitive optics and automated analysis.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Mixed financing | €12M | Commerzbank — ParticipantMittelständische Beteiligungsgesellschaft Niedersachsen — ParticipantState of Lower Saxony — Participant |